Navigation Links
Micromet to Present at the RBC Capital Markets Healthcare Conference
Date:12/5/2008

BETHESDA, Md., Dec. 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and Chief Executive Officer, Dr. Christian Itin, will participate in a panel discussion titled "Antibody Strategies For Fighting Cancer" at the RBC Capital Markets Healthcare Conference on December 10, 2008. The Conference will be held at the Westin Times Square in New York, NY.

    Forum:       The RBC Capital Markets Healthcare Conference
    Date:        Wednesday, December 10, 2008
    Time:        3:30 to 4:25 pm, Eastern Time
    Place:       The Westin Times Square
                 270 West 43rd Street
                 New York, New York 10036

    Webcast:      http://www.wsw.com/webcast/rbc95/

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, Maryland and Munich, Germany. The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company uses its proprietary BiTE(R) antibody platform to create a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease-related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clini
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Added to NASDAQ Biotechnology Index
2. Micromet, Inc. Reports Third Quarter 2008 Financial Results
3. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
4. Micromet Closes $40 Million Private Equity Placement
5. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
6. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
7. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
8. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
9. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
10. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
11. Micromet to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
(Date:8/26/2015)... SAN FRANCISCO , Aug. 26, 2015 /PRNewswire/ ... today that it has received a $1.5M Phase ... Health (NIH) to further develop its therapeutic agent ... unmet clinical need in end stage renal disease ... by the National Institute of Diabetes and Digestive ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
(Date:8/26/2015)... San Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... three major conferences to develop new business relationships with local sponsors in southern California. ... services to facilitate their drug development processes and regulatory pathways., , ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... S*BIO Pte Ltd today announced that,the U.S. ... drug,designation to SB1518, its potent and orally-active JAK2 ... FDA accepted S*BIO,s,application upon review of preclinical data ... very good,tolerability of the JAK2 inhibitor., "We ...
... 13 Johnson & Johnson today announced that,Professor ... Sir,Ravinder N. Maini, FRCP, FMedSci, FRS of the ... named the recipients of the,2008 Dr. Paul Janssen ... of world-renowned scientists., The award salutes the ...
... May 12 Meditor Pharmaceuticals Ltd.,announced today the appointment ... Advisor to the company., Dr. Schachner has been ... will now take a more active role in the ... Head of the Cardiac Surgery,Department at Wolfson Medical Center ...
Cached Biology Technology:S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders 2Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 2Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 3Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 4Two New Appointments at Meditor Pharmaceuticals Ltd. 2
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... new extinct camel species by University of Florida scientists sheds ... containing more than half the world,s biodiversity and some of ... the Journal of Vertebrate Paleontology , the study is ... part of an international project in Panama. Funded with a ...
... While some scientists report engineering a super virulent strain of ... significant percentage of the human population, another group of researchers ... one day help mitigate the deadly effects of all flu ... of the Journal of Leukocyte Biology , ...
... will soon host its annual Spring Review from 5 ... be held at 950 Glebe Road, Suite 210, in ... assessment of AFOSR,s research portfolio. , Since its ... in extramural basic research programs at leading universities and ...
Cached Biology News:UF scientists name new ancient camels from Panama Canal excavation 2UF scientists name new ancient camels from Panama Canal excavation 3New light shed on cause of lung injury in severe flu 2